Group 1 - The stock price of Saily Medical (603716) closed at 28.41 yuan as of August 15, 2025, representing a 2.93% increase from the previous week's price of 27.6 yuan [1] - The highest intraday price reached 31.31 yuan on August 13, 2025, while the lowest intraday price was 27.55 yuan on August 11, 2025 [1] - The total market capitalization of Saily Medical is currently 5.427 billion yuan, ranking 18th out of 31 in the pharmaceutical commercial sector and 3060th out of 5152 in the A-share market [1] Group 2 - The actual controller of the company, Mr. Wen Wei, has completed the release of the pledge on 3,000,000 shares, reducing his pledged shares to 5,300,000, which is 55.01% of his holdings and 2.77% of the total share capital [1] - The cumulative pledged shares by the controlling shareholder, Saihai Technology, and Mr. Wen Wei amount to 19,300,000 shares, representing 61.71% of their total holdings and 10.10% of the total share capital [1] Group 3 - The convertible bond "Saily Convertible Bond" will pay interest on August 21, 2025, for the period from August 21, 2024, to August 20, 2025 [2] - The total issuance amount of the convertible bond is 543.31 million yuan, with an interest payment of 2.50 yuan per bond (including tax) [2] - The interest payment record date is August 20, 2025, with the ex-dividend date and payment date both set for August 21, 2025 [2]

证券之星消息，塞力医疗(603716)08月15日在投资者关系平台上答复投资者关心的问题。 塞力医疗回复：尊敬的投资者，您好！早在2022年，塞力医疗便积极布局脑科学数字疗法领域，公司依 托旗下专注于智慧医疗数智转型及创新应用场景的子公司——海思太科（武汉）医疗科技有限公司，联 合浙江大学医学院附属第一医院精神卫生中心部署精神疾病全病程数智系统"海思灵曦"。作为面向国家 2030"脑计划与类脑研究"项目的重要成果，"海思灵曦"是针对抑郁症、双相情感障碍等主要精神疾病的 数字化辅助管理软件。该软件依托人工智能及互联网技术构建脑科学及类脑研究知识图谱，形成了面向 科研人员、医生和患者三方的前端用户功能工具平台。2024年4月，海思太科与浙大一院精神卫生中心 开启脑计划2030-脑计划与类脑研究"常见多发病防治研究"国家级重点专项计划，并同时在全国14家头 部医疗机构多中心同步开展。2025年初，塞力医疗联合华为技术、脑机智能全国重点实验室胡少华教授 团队签署精神医学数字疗法的战略合作框架。三方以华为算力基础设施为支撑，结合脑机智能全国重点 实验室科研资源与临床数据，探索脑科学大模型在精神医学中的应用，推动行业从经 ...

Core Viewpoint - The company, Saily Medical (603716.SH), is actively investing in the field of digital therapies for brain science, focusing on mental health management through innovative technology and strategic partnerships [1] Group 1: Company Initiatives - In 2022, Saily Medical began its strategic layout in the digital therapy sector for brain science, leveraging its subsidiary, Haisitai Medical Technology Co., Ltd., to develop a comprehensive digital management system for mental illnesses [1] - The "Haisilingxi" system, developed in collaboration with Zhejiang University First Affiliated Hospital's Mental Health Center, targets major mental disorders such as depression and bipolar disorder [1] - A national key project under the "Brain Plan 2030" was initiated in April 2024, involving multi-center studies across 14 leading medical institutions [1] Group 2: Strategic Partnerships - In early 2025, Saily Medical signed a strategic cooperation framework with Huawei Technologies and Professor Hu Shaohua's team from the National Key Laboratory of Brain-Machine Intelligence to explore the application of brain science models in psychiatry [1] - The collaboration aims to transition the industry from experience-driven to data-driven approaches, utilizing Huawei's computational infrastructure and clinical data [1] Group 3: Technological Development - By April 2025, Saily Medical established an AI diagnostic technology research center (TAIDx Lab) in Shanghai, focusing on rapid molecular diagnostics for infections and critical conditions, as well as digital therapies for brain science [1] - The lab is equipped with Huawei's Ascend AI cluster and Kunpeng servers to efficiently process large volumes of data, creating a secure and closed-loop system involving medical institutions, pharmaceutical companies, and regulatory bodies [1] - Future efforts will concentrate on advancing technology development and application to build core competitive advantages through technological barriers [1]

证券之星消息，8月14日医药商业板块较上一交易日下跌1.35%，塞力医疗领跌。当日上证指数报收于 3666.44，下跌0.46%。深证成指报收于11451.43，下跌0.87%。医药商业板块个股涨跌见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入(元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 603939 | 益丰药房 | 1562.54万 | 9.35% | -99.62万 | -0.60% | -1462.92万 | -8.75% | | 000028 | 国药一致 | 577.41万 | 5.26% | -431.37万 | -3.93% | -146.04万 | -1.33% | | 000411 | 英特集团 | 503.55万 | 6.47% | 507.34万 | 6.52% | -- 1010.88万 | -13.00% | | 002788 | 鹭燕医药 | 240.24万 | 4.17% | 602.82万 | 10.47% | -8 ...

截至2025年8月13日15时，塞力医疗最新股价为31.09元，较前一交易日收盘价上涨1.91元。当日开盘价 为29.04元，最高触及31.31元，最低下探28.59元，成交量为55.62万手，成交金额达16.71亿元。 风险提示：以上内容仅供参考，不构成投资建议。市场有风险，投资需谨慎。 塞力医疗属于医药商业板块，公司主营业务为医疗商业和工业业务。2024年财务数据显示，其商业业务 收入占比达97.09%，工业业务收入占比2.91%。 来源:金融界 8月12日晚间，公司发布公告称实际控制人温伟已办理完成300万股股份的解除质押手续。本次解除质押 后，温伟累计质押股份数降至530万股，占其持股比例的55.01%。公司控股股东及实际控制人合计质押 股份数为1930万股，占公司总股本的10.1%。 8月13日主力资金净流入1.09亿元，占流通市值的1.84%。近五个交易日主力资金累计净流入1.44亿元， 占流通市值的2.42%。 ...

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 301408 | 华人健康 | 15.11 | -1.76% | 17.96万 | 2.71亿 | | 300937 | 药易购 | 30.05 | -1.60% | 4.53万 | 1.36亿 | | 301015 | 百洋医药 | 25.98 | -1.55% | 29.18万 | 7.77亿 | | 600272 | 开开实业 | 13.87 | -1.42% | 6.94万 | 9642.32万 | | 301126 | 达嘉维康 | 13.25 | -1.41% | 14.39万 | 1.91亿 | | 603122 | 合富中国 | 7.23 | -1.36% | 6.01万 | 4356.44万 | | 002589 | 瑞康医药 | 3.05 | -1.29% | 43.86万 | 1.34亿 | | 301017 | 款玉平民 | 13.20 | -0.98% | 4.94万 | 6532.05万 | | 605266 | 健之佳 ...

来源：金融界 8月13日，DRG/DIP概念上涨2.42%，今日主力资金流入4.56亿元，概念股13只上涨，6只下跌。 主力资金净流入居前的分别为荣科科技（4.22亿元）、塞力医疗（1.09亿元）、数字认证（7544.17万 元）、东华软件（5875.2万元）、太极股份（5268.54万元）。 序号代码名称最新价涨跌幅主力净流入主力净占比1300290荣科科技22.9220.04.22亿元24.34%2603716塞 力医疗31.096.551.09亿元6.54%3300579数字认证37.759.267544.17万元5.98%4002065东华软件 9.611.85875.20万元3.97%5002368太极股份26.372.615268.54万元7.4%6300078思创医惠4.050.25100.71万 元0.63%7688246嘉和美康35.393.06-1.15万元-0.01%8600718东软集团10.051.01-27.36万元-0.12%9300168 万达信息7.970.38-383.65万元-1.85%10688579山大地纬11.78-0.67-394.36万元-5.69% ...

资金流向方面，今日主力资金净流入1.09亿元，占比成交额6.54%。其中，超大单净流入8233.52万元、 占成交额4.93%，大单净流入2691.33万元、占成交额1.61%，中单净流出流出8469.74万元、占成交额 5.07%，小单净流出2455.11万元、占成交额1.47%。 塞力医疗最新一期业绩显示，截至2025一季报，公司营业总收入2.87亿元、同比减少40.75%，归属净利 润1432.09万元，同比减少553.66%，扣非净利润2846.33万元，同比减少3228.81%，流动比率1.931、速 动比率1.591、资产负债率58.57%。 金融界消息 截至2025年8月13日收盘，塞力医疗（603716）报收于31.09元，上涨6.55%，换手率 29.12%，成交量55.62万手，成交金额16.71亿元。 通过天眼查大数据分析，塞力斯医疗科技集团股份有限公司共对外投资了70家企业，参与招投标项目 146次，知识产权方面有商标信息9条，专利信息7条，此外企业还拥有行政许可26个。 来源：金融界 天眼查商业履历信息显示，塞力斯医疗科技集团股份有限公司，成立于2004年，位于武汉市，是一家以 从事 ...

券商科创债今年来发行规模超过400亿元。头部券商专项支持科技创新领域的力度不断加大。申万宏源、中原证券等券商相继获批债券发行额度。7月A股新 开户196.36万户，同比增长70.5%，环比增长19.27%。截至7月末，今年以来A股累计新开1456.13万户。新增开户数据反映出市场活跃度的提升，为券商业务 发展提供支撑。 创新药概念股再度活跃获政策支持 8月13日，A股市场呈现震荡上行态势。创业板指数表现突出，半日涨幅达到2.81%。沪指突破2024年10月8日高点，创下2021年12月17日以来新高。沪深两 市半日成交额达1.32万亿元，较上个交易日放量1181亿元。券商股盘中出现异动拉升，创新药概念股同步走强，为市场注入新的活力。 券商板块异动拉升显现资金青睐 券商股在盘中表现活跃，国盛金控连续两个交易日涨停。证券板块主力资金净流入28.45亿元，位居各行业板块资金流入榜首位。东方财富全天成交额达 110.44亿元，居全市场第一位。金融科技方向上，中科金财、同花顺、大智慧等个股领涨。 市场上涨期间，券商板块受到资金追捧。背后体现的是"卖斧子"的投资逻辑。过去券商主要依靠佣金收入，现在这把"斧子"的载体正转向 ...

Group 1 - The core viewpoint of the news is that the brain-computer interface concept stocks in the A-share market have shown strong performance, with several companies experiencing significant price increases [1] Group 2 - Company performance highlights include: - Innovation Medical (002173) saw a price increase of 10.00%, with a total market capitalization of 9.995 billion and a year-to-date increase of 184.55% [2] - Pulite (002324) increased by 7.51%, with a market cap of 15.9 billion and a year-to-date increase of 50.88% [2] - Chengyitong (300430) rose by 6.65%, with a market cap of 6.657 billion and a year-to-date increase of 59.67% [2] - Saily Medical (603716) increased by 5.45%, with a market cap of 5.878 billion and a year-to-date increase of 326.18% [2] - Sanbo Brain Science (301293) rose by 3.79%, with a market cap of 12.9 billion and a year-to-date increase of 44.76% [2] - The MACD golden cross signal formation indicates a positive trend for these stocks [1]